Status:
COMPLETED
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Non-squamous, Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Characteristics of patients with Neuregulin-1 (NRG1) gene fusion-positive solid tumors treated with afatinib, and characteristics of those treated with another systemic therapy.
Eligibility Criteria
Inclusion
- Adults, 18 years of age or older, at the time of diagnosis with any solid tumor.
- Confirmed NRG1 gene fusion in any solid tumor.
- Initiated afatinib or other systemic therapy (in any line of therapy) for treatment of a solid tumor with NRG1 gene fusion on or after 01/01/2017 through 03/31/2020.
- Followed up for ≥3 months after initiation of afatinib or other systemic therapy (unless deceased prior to 3 months of follow-up).
Exclusion
- \- Treatment with any Tyrosine kinase inhibitor (TKI)/ErbB-directed therapy other than afatinib
Key Trial Info
Start Date :
October 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 20 2021
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04750824
Start Date
October 15 2020
End Date
December 20 2021
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardinal Health
Dublin, Ohio, United States, 43017